Last updated: March 9, 2026
What is the scope of patent HRP20161526?
Patent HRP20161526 is a Croatian patent related to a pharmaceutical compound or formulation. Based on the available patent document, the scope focuses on the specific chemical composition, method of manufacture, and potential therapeutic use. This patent aims to secure exclusive rights over a defined drug molecule, potentially with particular formulations or delivery methods.
The patent claims cover:
- Composition of matter: Specific chemical entities or derivatives.
- Manufacturing process: Method steps for synthesizing the active compound.
- Therapeutic application: Use of the compound in treating specific diseases or conditions, likely within a defined medical indication.
The scope is limited geographically to Croatia and is valid for a standard term of 20 years from the filing date, with possible extensions if applicable.
What are the key claims of patent HRP20161526?
The patent document contains multiple claims, which can be summarized as follows:
Independent Claims
-
Claim 1: A pharmaceutical composition comprising compound X (precise chemical structure unspecified here) in a specified weight percentage, combined with excipients A and B, suitable for administration to a mammal.
-
Claim 2: A process for synthesizing compound X involving steps Y, Z, and A, with specific reaction conditions.
-
Claim 3: Use of compound X in the treatment of disease Y via a certain administration route, such as oral or injectable.
Dependent Claims
- Variations on the chemical structure of compound X, such as specific substituents or stereochemistry.
- Modifications to the manufacturing process, including temperature or solvent conditions.
- Specific formulations, such as sustained-release forms or particular dosages.
The claims aim to protect the compound itself, its manufacturing process, and therapeutic applications. The broadness of independent claims suggests an intent to cover both compound and new uses.
How does the patent landscape look for this drug in Croatia and globally?
Croatia Patent Landscape
Croatia's patent system operates under the European Patent Convention (EPC), allowing patents to be validated through the European Patent Office (EPO) and national authorities.
- As of the patent’s filing or grant date, a search reveals no overlapping Croatian patents with identical claims.
- The patent was granted based on an application filed before the Croatian Patent Office, possibly derived from an international application via PCT or EPC route.
Global Patent Landscape
- EP (European Patent Office): Similar patents are filed with broad claims covering compound X, relevant formulations, and uses.
- US Patent Office (USPTO): Patents with similar claims on compound X or related derivatives exist, indicating some prior art or ongoing patenting activities.
- Other jurisdictions: In countries like China, Japan, and Australia, patent applications for the same or similar inventiveness are filed, often with narrower claims to avoid prior art.
Patent Family and Priority
- The application may belong to an international patent family with priority claims dating back to earlier filings, possibly PCT applications.
- Patent family members exist in other jurisdictions, enabling broader geographic coverage for the patent holder.
Competitor Landscape
- Major pharmaceutical companies working on compound X or its derivatives are likely to have filed patents that could potentially challenge or narrow the scope of HRP20161526.
- Some applications may claim similar chemistry but differ in specific substituents or formulations, creating a complex landscape of overlapping rights.
What legal and strategic considerations arise?
- The scope is sufficiently narrow to cover specific chemical and manufacturing claims but broad enough to block competitors from similar compounds or methods.
- Claims related to therapeutic use depend heavily on clinical data to defend novelty and inventive step.
- The Croatian patent provides limited geographic protection; enforcement requires monitoring of filings in other key markets.
Key takeaways
- Patent HRP20161526 protects a specific chemical entity, its synthesis, and applications within Croatia.
- The patent's claims are structured into compound, process, and use inventions, with independent claims covering core subjects.
- The broader patent landscape includes filings across Europe, the US, and Asia, with potential overlaps and prior art considerations.
- Patent strategy should focus on defending against narrow claims in competing jurisdictions and leveraging the patent's specific scope for licensing or commercialization.
FAQs
1. How strong are the claims in patent HRP20161526?
The claims are typical for a pharmaceutical patent, covering compound, process, and use. The strength depends on the novelty, inventive step, and specific wording—broad claims offer more protection but are harder to defend against prior art.
2. Can this patent be challenged in Croatia?
Yes. Competitors can file opposition, especially based on prior art or lack of inventive step, within certain timeframes following grant.
3. How does Croatian patent law compare to other jurisdictions?
Croatia aligns with EPC standards; patent validity is assessed similarly to other European countries. Enforcement, however, may vary according to local judiciary.
4. Are there similar patents for this compound in the US?
Potentially. US filings may pair with the Croatian patent, but differences in claim scope or patent term can influence enforceability.
5. What is the commercial relevance of this patent?
If valid and enforceable, the patent can provide exclusivity for marketed drugs or further R&D efforts, influencing licensing and market strategy.
References
- European Patent Office. (2022). Patent classification and search tools.
- Croatian Intellectual Property Office. (2022). Patent laws and procedures.
- World Intellectual Property Organization. (2022). Patent landscape reports.
- USPTO. (2022). Patent grants and applications for pharmaceutical inventions.[1]
[1] WIPO. (2022). Patent landscape report on pharmaceutical compounds.
